Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 337 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Current regimen Clear all
Completed No phase listed Observational

Therapeutic Research in Multiple Myeloma

NCT00572338
View directory record Official record
Conditions
Multiple Myeloma
Interventions
No drugs are involved
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
6,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.

NCT03461718
View directory record Official record
Conditions
Administration and Dosage of Ketamine, Endoscopic Sedation
Interventions
Ketamine, Midazolam injection, Fentanyl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

NCT04021290
View directory record Official record
Conditions
HIV Infections
Interventions
DTG/3TC FDC, CAR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Not applicable Interventional

Appendectomy Versus Non-Operative Treatment For Acute Non-Perforated Appendicitis in Children

NCT02687464
View directory record Official record
Conditions
Appendicitis
Interventions
Non-operative treatment, Appendectomy
Other · Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
5 Years to 16 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Adaptive Treatment Strategy for Adolescent Depression-Continuation

NCT02017535
View directory record Official record
Conditions
Adolescent Depression
Interventions
Fluoxetine, Interpersonal Psychotherapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 19, 2026, 10:10 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Baricitinib Curative Repression of HIV-1

NCT07209267
View directory record Official record
Conditions
HIV Infection, HIV
Interventions
Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Not applicable Interventional Results available

Pain Relief for OsteoArthritis Through Combined Treatment (PROACT)

NCT03884374
View directory record Official record
Conditions
Osteoarthritis of Knee
Interventions
Focused Breathing and Attention Training (BAT), Standard Breathing and Attention Training (BAT), Transcranial Direct Current Stimulation (tDCS), Sham Transcranial Direct Current Stimulation (tDCS)
Behavioral · Device
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 85 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 19, 2026, 10:10 AM EDT
Active, not recruiting Phase 1 Interventional

Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

NCT03549442
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Clinical Utility of Resistance Training for Improving Cardiovascular Disease Risk in Post-Menopausal Women

NCT03752060
View directory record Official record
Conditions
Cardiovascular Risk Factor, Menopause Related Conditions, Neuromuscular Function, Aerobic Capacity, Inflammation
Interventions
Resistance Exercise, Aerobic Exercise
Behavioral
Lead sponsor
Oklahoma State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 19, 2026, 10:10 AM EDT
Recruiting Phase 2 Interventional

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

NCT06910124
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Linvoseltamab, Lenalidomide
Biological · Drug
Lead sponsor
Dickran Kazandjian, MD
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

NCT02502149
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients

NCT01624948
View directory record Official record
Conditions
BK Virus Infection
Interventions
Everolimus, Mycophenolic acid dose reduction
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Phase 4 Interventional

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

NCT04388904
View directory record Official record
Conditions
HIV-1-infection
Interventions
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
Drug
Lead sponsor
The Crofoot Research Center, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 19, 2026, 10:10 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old

NCT05329961
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Gardasil9
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
4 Years to 8 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 10:10 AM EDT
Terminated Phase 3 Interventional Results available

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

NCT05220397
View directory record Official record
Conditions
Kidney Transplant Recipient
Interventions
Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
Biological · Other
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations

NCT01156610
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Tobacco Treatment
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 19, 2026, 10:10 AM EDT
Terminated Phase 2 Interventional Results available

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

NCT02862574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Andecaliximab, Placebo, Methotrexate, TNF Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 19, 2026, 10:10 AM EDT
Completed No phase listed Observational

Impact of Iron Supplementation Treatment on Brain Iron Concentrations

NCT04144790
View directory record Official record
Conditions
ADHD, Iron-deficiency, Restless Legs Syndrome, Periodic Limb Movement Sleep Disorder
Interventions
ferrous sulfate
Dietary Supplement
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
5 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 19, 2026, 10:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Medibio DDA Confirmatory Performance Study

NCT03529513
View directory record Official record
Conditions
Major Depressive Episode
Interventions
Medibio Depression Diagnostic Aid, Mini International Neuropsychiatric Interview, Hamilton Rating Scale for Depression - 17 Item
Diagnostic Test
Lead sponsor
Medibio Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
6
States / cities
Garden Grove, California • Torrance, California • Mason, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 19, 2026, 10:10 AM EDT
Terminated Not applicable Interventional Results available

Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT03772717
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
Device · Other
Lead sponsor
Emory University
Other
Eligibility
5 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 19, 2026, 10:10 AM EDT
Terminated Early Phase 1 Interventional

Is a Smartphone Application Effective as an Oral Medication Adherence Aid

NCT01968876
View directory record Official record
Conditions
Hypertension, Diabetes, Dyslipidemia
Interventions
Medication Adherence Smartphone App
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Phase 4 Interventional Results available

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

NCT00735072
View directory record Official record
Conditions
HIV Infection
Interventions
Placebo, Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 19, 2026, 10:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 19, 2026, 10:10 AM EDT